Look, I'll be straight with you: when Goldman Sachs adds a stock to its Asia-Pacific "Conviction List," half the market genuflects like it's divine revelation. The other half — where I belong — raises an eyebrow and asks: "Hold up, what's the play here?"
Because if history teaches us anything, it's that the recommendation lists from big investment banks have a, let's say, peculiar track record.
The Cold, Hard Facts
Goldman Sachs added Alibaba Group Holding (BABA) to its conviction list for the Asia-Pacific region. For those who don't speak Wall Street suit-speak: this means the bank's analysts consider BABA one of their best investment ideas in the region. This isn't some run-of-the-mill "buy" rating — this is the bank putting its face (and supposedly its reputation) on the line to say: "this one we're pounding our chest over."
And look, I won't lie: the timing is interesting.
The Context Nobody Explains Properly
Alibaba has been through its own personal hell the past few years. Ever since Jack Ma decided to run his mouth against Chinese regulators back in October 2020 — in a scene straight out of Walter White thinking he could stand up to Gus Fring — the company got pummeled from every direction.
Billion-dollar antitrust fine. Ant Group IPO canceled. Forced restructuring into six business units. A drop of more than 70% from its highs. A genuine trek through the desert.
But here's the point that matters: companies are not their worst headlines.
Alibaba is still a cash-generating beast. The cloud computing business is growing. The share buyback program is aggressive — we're talking billions of dollars in buybacks. And the price-to-earnings ratio? It's trading at multiples that would make Benjamin Graham jump out of his chair with his eyes sparkling.
The Problem with Blindly Trusting Goldman
Now, before you rush out to open a position, a cold shower.
Remember when Goldman Sachs was recommending subprime mortgage derivatives like they were gold? Yeah. The same Goldman that was selling that garbage to clients was betting against it internally. This isn't conspiracy theory — it's documented fact, investigated by the U.S. Senate.
Nassim Taleb has a perfect expression for this: "skin in the game." The question you should be asking isn't "did Goldman recommend it?" — it's "is Goldman buying for its own book under the same conditions?"
Because it's one thing for a 28-year-old analyst in New York to slap a "Buy" on an Excel model. It's a completely different thing for someone to put real money — money that hurts to lose — on the same thesis.
What's Really at Stake
The investment thesis for Alibaba isn't complicated. It's basically: "the market went overboard on China pessimism, and BABA is way too cheap for what it delivers."
And you know what? It might even be right.
The Chinese government changed its tone. Xi Jinping showed up smiling next to Jack Ma — a scene that seemed about as likely as the Joker having tea with Batman. Economic stimulus is coming. Tech regulation seems to have peaked.
But "might be right" is different from "is right." The geopolitical risk is still real. The Chinese economy is spinning its wheels. And investing in a Chinese company listed via ADR in the U.S. carries structural risks that most people don't even understand — including the risk of delisting.
The Question That Matters
I'm not here to tell you whether BABA is a buy or not. That would be falling into the same circus as those Instagram gurus with their "recommended portfolios" — who, curiously, never show their own account statements.
What I will tell you is this: if you're going to invest in Alibaba, let it be because you studied the balance sheet, you understood the risks, you have the stomach for Chinese volatility. Not because Goldman put it on a pretty list.
Because at the end of the day, when the shit hits the fan — and at some point it always does — Goldman will be protected with its billion-dollar hedges. And you?
